Nurix Therapeutics Appoints New CMO, Director
Ticker: NRIX · Form: 8-K · Filed: Mar 13, 2025 · CIK: 1549595
Sentiment: neutral
Topics: executive-appointment, board-of-directors, personnel-change
Related Tickers: NRIX
TL;DR
Nurix brings in a new CMO and adds a director to the board.
AI Summary
Nurix Therapeutics, Inc. announced on March 11, 2025, the appointment of Dr. Robert L. Kirk as Chief Medical Officer and the election of Ms. Jennifer L. Jones to its Board of Directors. The company also disclosed compensatory arrangements for certain officers, details of which are filed as exhibits.
Why It Matters
Changes in key leadership roles and board composition can signal strategic shifts or governance updates for the company.
Risk Assessment
Risk Level: low — This filing primarily concerns executive appointments and board changes, which are routine corporate governance events.
Key Players & Entities
- Nurix Therapeutics, Inc. (company) — Registrant
- Dr. Robert L. Kirk (person) — Appointed Chief Medical Officer
- Ms. Jennifer L. Jones (person) — Elected to Board of Directors
- March 11, 2025 (date) — Date of Earliest Event Reported
FAQ
Who has been appointed as the new Chief Medical Officer for Nurix Therapeutics?
Dr. Robert L. Kirk has been appointed as the new Chief Medical Officer.
Who has been elected to the Board of Directors at Nurix Therapeutics?
Ms. Jennifer L. Jones has been elected to the Board of Directors.
What is the exact date of the earliest event reported in this 8-K filing?
The date of the earliest event reported is March 11, 2025.
What other information is disclosed regarding officers in this filing?
The filing discloses compensatory arrangements for certain officers.
What is the state of incorporation for Nurix Therapeutics, Inc.?
Nurix Therapeutics, Inc. is incorporated in Delaware.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on March 13, 2025 by Dr. Robert L. Kirk regarding Nurix Therapeutics, Inc. (NRIX).